

Malaria in pregnancy: the relevance of animal models for vaccine development

Justin Doritchamou, Andrew Teo, Michal Fried & Patrick E Duffy

Malaria during pregnancy due to *Plasmodium falciparum* or *P. vivax* is a major public health problem in endemic areas, with *P. falciparum* causing the greatest burden of disease. Increasing resistance of parasites and mosquitoes to existing tools, such as preventive antimalarial treatments and insecticide-treated bed nets respectively, is eroding the partial protection that they offer to pregnant women. Thus, development of effective vaccines against malaria during pregnancy is an urgent priority. Relevant animal models that recapitulate key features of the pathophysiology and immunology of malaria in pregnant women could be used to accelerate vaccine development. This review summarizes available rodent and nonhuman primate models of malaria in pregnancy, and discusses their suitability for studies of biologics intended to prevent or treat malaria in this vulnerable population.

Among *Plasmodium* species that infect humans, *P. falciparum* is the most deadly. Despite long-term exposure to *P. falciparum* infection, women are again susceptible to *P. falciparum* infection during pregnancy, particularly primigravidae^{1,2}. Similarly, susceptibility to *P. vivax* increases during pregnancy, and while the susceptibility to *P. vivax* infection is greatest in primigravidae, the risk of disease is greatest in multigravidae^{3,4}. The adverse effects of malaria in pregnancy (MiP) on the fetus as well as the mother are well-documented, particularly for *P. falciparum*^{1–3}. Abortion, stillbirth, miscarriage, intrauterine growth retardation (IUGR; see **Box 1** for glossary), pre-term delivery (PTD), low birth weight (LBW), severe maternal anemia, and multiple clinical symptoms, including acute severe syndromes, have been reported among malaria-infected pregnant women^{1–8}. These sequelae lead to increased maternal and fetal mortality and morbidity rates^{5,7}.

Malaria presentation differs between women with low and high malaria immunity. The former often experience acute severe syndromes, such as respiratory distress and cerebral malaria, and these women are at high risk for mortality without prompt treatment⁹. The latter may remain asymptomatic or paucisymptomatic during chronic infections which nevertheless lead to poor outcomes like severe maternal anemia that increase mortality risk.

The sequestration of *P. falciparum*-infected erythrocytes (IEs) in the intervillous spaces of the placenta is a hallmark of placental malaria (PM) pathology^{10,11}. Although *P. vivax*-MiP also causes maternal anemia and LBW^{12–14}, disease severity is generally less than that of *P. falciparum*-MiP, and there has been no evidence of placental sequestration of *P. vivax*-IEs. Placental *P. falciparum* parasites, as well as those isolated from women during pregnancy, selectively

bind to chondroitin sulfate A (CSA), a glycosaminoglycan expressed by syncytiotrophoblast, which localizes to the surface of placental villi as well as to fibrinoid in the intervillous spaces^{15–21}. Placental sequestration of parasites can elicit an inflammatory infiltrate in the intervillous spaces, a typical feature in primigravidae that is specifically associated with poor outcomes including severe maternal anemia and LBW of newborns².

VAR2CSA, a member of the *P. falciparum* erythrocyte membrane protein 1 (PfEMP1) family, is highly expressed by placental *P. falciparum*, and has been identified as the major parasite surface ligand for the CSA receptor^{22–24}. The *var* genes that encode PfEMP1 proteins are unique to the *P. falciparum* genome^{25,26}, and regulation of *var* genes ensures that only one PfEMP1 variant is expressed on the surface of each IE²⁰. Pregnant women become resistant to PM as they acquire antibodies against CSA-binding parasites over successive pregnancies, suggesting a role in protection of women against poor pregnancy outcomes^{22,27–30}. These findings support the development of a PM vaccine based on VAR2CSA that targets placental *P. falciparum* parasites³¹. No orthologs of VAR2CSA have been identified in *P. vivax*, and as the pathogenesis of *P. vivax*-MiP remains unclear, there is no similar path to develop a vaccine for this syndrome.

In areas of stable transmission, current malaria preventive measures include intermittent preventive therapy during pregnancy (IPTp) with antimalarial drugs and the use of insecticide treated nets. However, emerging resistance to both antimalarial drugs and insecticides can render such measures ineffective. In areas of unstable transmission, women with low immunity to malaria must be actively screened and treated promptly to prevent severe sequelae³².

Laboratory of Malaria Immunology & Vaccinology, National Institute of Allergy and Infectious Disease, National Institutes of Health, Rockville, Maryland, USA. Correspondence should be addressed to P.E.D (Patrick.Duffy@nih.gov)

Box 1 | Glossary of terms and concepts

Chondroitin sulfate A (CSA): A low sulfated glycoaminoglycan expressed on the surface of syncytiotrophoblasts, in intervillous spaces, and within fibrinoid deposits. CSA is the major placental receptor to which IEs bind in the placenta, causing placental sequestration.

Infected Erythrocyte (IE): During malaria infection, parasites invade erythrocytes where they develop within a parasitophorous vacuole in the erythrocyte cytoplasm. The parasite exports proteins to the infected erythrocyte surface membrane.

Intermittent preventive treatment during pregnancy (IPTp): Regular anti-malarial treatments during pregnancy that lead to improved pregnancy outcomes in malaria-endemic areas. Doses of anti-malarial drugs are administered to pregnant women no more than once a month after the first trimester of pregnancy. This preventive strategy is now implemented in many malaria-endemic countries, despite the emergence of drug-resistant parasites.

Intrauterine growth restriction (IUGR): Also known as intrauterine growth retardation, it refers to poor growth of the fetus as determined by weight-for-gestational age during the pregnancy. Restriction of oxygen and nutrients required for normal development of the fetus may be one of the causes of IUGR. IUGR has been associated with pre-term delivery and is a major risk factor for infant mortality.

Low birth weight (LBW): LBW has been defined by the World Health Organization (WHO) to classify neonates with birth weights below 2500 g. LBW is a common sequela of placental malaria and has been associated with infant mortality.

Malaria in pregnancy (MiP): Infection with *Plasmodium spp* during pregnancy. *P. falciparum* infection during pregnancy leads to placental malaria with sequestration of parasitized erythrocytes in intervillous spaces. Other species of *Plasmodium* cause systemic malaria infection during pregnancy without placental sequestration. Many terms are used to designate malaria infection detected in pregnant women, named MiP in this review.

Multigravidae: In malaria-endemic areas, women become resistant over successive pregnancies to PM-related pregnancy outcomes. Multigravid women develop protective immunity against CSA-binding *P. falciparum* parasites, preventing parasite sequestration in the placenta.

Primigravidae: In malaria-endemic areas, first-time pregnant women are the most susceptible to PM and its related sequelae, due to the lack of immunity to PM parasites. Primigravid women have low levels of antibodies against CSA-binding *P. falciparum* parasites.

***P. falciparum* erythrocyte membrane protein 1 (PfEMP1):** PfEMP1 proteins constitute a major VSA family expressed on *P. falciparum* infected erythrocytes. These proteins are encoded by a family of *var* genes comprising approximately 60 copies within every parasite genome. The proteins localize to electron-dense IE surface knobs and mediate interactions between the *P. falciparum* IE and endothelial receptors to avoid splenic clearance and the immune system. Different members of this family of proteins have been associated with adhesion to various receptors and therefore sequestration in corresponding tissues, such as CSA in the placenta.

Placental malaria (PM): A hallmark of malaria infection during pregnancy, PM is characterized by sequestration of *P. falciparum*-infected erythrocytes in the maternal intervillous spaces. Although *P. knowlesi* is also known as a placenta sequestering parasite in nonhuman primates, no evidence of *P. knowlesi* placental sequestration in humans exists. Placental sequestration leads to inflammation of the placenta.

Pre-term delivery (PTD): According to the World Health Organization, a PTD is defined as a baby born alive before 37 weeks of pregnancy are completed. Pregnant women who develop PM are more likely to experience PTD.

Sequestration: Sequestration is defined as accumulation of IEs in deep vascular beds including the placenta, and not just evidence of IEs “adhering” to tissue.

VAR2CSA: A member of the PfEMP1 family highly expressed by *P. falciparum* isolated from the placenta. VAR2CSA-expressing parasites selectively bind placental tissue on the placental receptor chondroitin sulfate A (CSA), and are differentially recognized by antibodies from protected pregnant women. VAR2CSA is the leading candidate to be developed as a vaccine against placental malaria.

Variant surface antigens (VSAs): Large families of protein paralogs expressed on the surface of IEs by different pathogens in order to evade the immune response as part of their survival mechanism. Parasites sequentially switch the expression of different VSAs that are targeted by the immune system. Different families of proteins are expressed as VSAs by *Plasmodium* and other pathogens. The expression of the *Plasmodium interspersed repeat* (PIR) multigene family of proteins is common to all *Plasmodium* species, although their function(s) remains unknown. Other VSAs are species-specific, such as SICAvAr (in *P. knowlesi*) or PfEMP1 (in *P. falciparum*).

Therefore, an effective vaccine that can protect pregnant women against MiP in high and low transmission zones is urgently needed. However, the lack of suitable models to understand biological mechanisms involved in disease and protective immunity impedes vaccine development. Furthermore, the lack of suitable models to assess vaccine efficacy limits testing of candidate immunogens to laborious clinical trials that may yield less effective vaccines.

In this review, we describe existing animal models of MiP and discuss the relevance of each model in the context of PM vaccine development (see **Box 2** and **Fig. 1** for summary of models).

Rodent models for placental malaria

Rodents are attractive for MiP research because of their short reproductive cycles, highly reproducible course of parasitemia in inbred animals, and less restrictive ethical concerns. Study conditions can be easily manipulated to model aspects of human epidemiology, such as timing of parasite exposure (for example, before pregnancy, during pregnancy, or both), or intensity of exposure (to model high, moderate and low transmission settings).

Rodent studies have demonstrated that MiP can result in complications to both dams and their offspring similar to those seen

Box 2 | Key features of *P. falciparum* malaria in pregnant women by which to assess animal models

Parasitemia

Higher density of parasites in placental versus peripheral blood.
 Chronicity of infection: long term parasite carriage.
 Parasite recrudescence during pregnancy.

Placental sequestration

Accumulation of mature stage parasites in maternal vascular spaces of placenta.
 Inflammatory infiltrate in maternal vascular spaces of placenta.
 Evidence of placental damage: syncytiotrophoblastic necrosis, partial loss of microvilli, fibrinoid deposits.

Phenotype of the parasites

Adhesion of placental parasites to CSA expressed by syncytiotrophoblast.
 Upregulation of the parasite ligand VAR2CSA involved in placental sequestration.

Acquisition of protective immunity over successive malaria-exposed pregnancies

Clinical resistance acquired over successive pregnancies.
 Antibodies to placental parasites associated with clinical resistance.
 Antibodies to placental parasites with broadly neutralizing activity.

in humans, such as abortions and poor placental development^{9,33}. Some evidence for a distinct pregnancy parasite phenotype, parasite adhesion to placental receptors, placental sequestration of parasites, and immunity to placental parasites, have all been reported^{34–40}. However, placental sequestration of parasites has generally not been a prominent feature of rodent MiP, unlike human MiP. Further, the absence of *PfEMP1* homologs in rodent malaria parasites impedes mechanistic studies of these key virulence markers, as well as pre-clinical testing of VAR2CSA-based interventions. In this review, sequestration is defined as accumulation of IE in the placenta, and not just evidence of IE “adhering” to placental tissue.

Infection during pregnancy (non-immune model)

The use of non-immune pregnant rodents provides opportunities to understand the pathological outcomes of infection during pregnancy. This may be particularly relevant to MiP in women in areas of unstable transmission and travelers, who lack immunity and are at high risk of acute severe syndromes.

In non-pregnant non-immune C57B/6 mice, control of *P. chabaudi* infection is mediated first by pro-inflammatory cytokines and then by antibody-mediated responses^{41,42}. In pregnant non-immune mice, *P. chabaudi* infection increases levels of pro-inflammatory cytokines such as interferon- γ , tumor necrosis factor- α , and interleukin-1 β (IL) in the plasma. High levels of anti-inflammatory cytokines (such as IL-10) have also been observed, though these were insufficient to prevent fetal loss^{37,39}. Conversely, *P. berghei* in non-immune pregnant mice was reported to cause increased levels of IL-17 and reduced levels of IL-10 that were associated with lower birth weights of offspring³⁵, although other studies have not seen these relationships^{43–45}. Increased levels of complement C5a and C5a receptor in infected mice have been associated with poor fetal growth, and mutant mice lacking the C5a receptor delivered significantly heavier offspring⁴⁶. *P. berghei* infection during pregnancy leads to dysregulated angiopoietin levels, which are also associated with fetal growth restriction⁴⁷. These observations with *P. chabaudi* and

P. berghei suggest that dysregulated levels of cytokines, complement factors, and angiogenic factors (such as angiopoietin 1 and 2) may impair placental formation, resulting in poor placental function^{38,46,48}, that contributes to poor fetal outcomes^{47,49}.

In non-pregnant rodents, *P. chabaudi* can sequester in various organs³⁴, but it remains unclear the degree to which sequestration occurs in the placenta. Poovassery *et al.* reported that *P. chabaudi* can accumulate in the placentae of infected pregnant mice, with significantly higher parasite densities in placental than peripheral blood only in mice that suffered abortion⁵⁰. Meanwhile, a recent study of *P. chabaudi*-infected pregnant mice showed no significant difference in placental and peripheral parasite densities, and no apparent accumulation of mature parasite forms in the placenta by histological examination⁴⁰. The absence of *var* genes, especially VAR2CSA, could explain why *P. chabaudi* parasites do not sequester in the placenta, although the absence of *var* genes does not preclude sequestration in other vascular beds. Of note, *P. vivax* also lacks *var* genes and shares several protein orthologs such as *pir* genes that encode a variant antigen family with *P. chabaudi*⁴⁵. Since *P. vivax* MiP does not involve placental parasite sequestration^{12,13}, and *in vitro* studies have failed to identify a *P. vivax* adhesion phenotype related to MiP⁵¹, systemic infection in the mother may more likely explain poor pregnancy outcomes. *P. chabaudi* infection in pregnant mice does not result in placental abnormalities or significant monocyte infiltration, but nevertheless offspring had significantly lower birth weights compared to offspring from naïve dams^{40,50}. Hence, *P. chabaudi* should be further evaluated as a model of *P. vivax* MiP.

P. berghei has been demonstrated to bind to mouse placenta *ex vivo*, and this adhesion was reduced by pre-incubating *P. berghei* IEs with CSA and/or hyaluronic acid (HA)^{9,36}; the involvement of HA in the binding of *P. falciparum*-IEs to human placenta is questionable⁵². In a subsequent study using intravital imaging techniques, the authors provided insight into interactions between *P. berghei*-IEs and trophoblast: no stationary IEs were observed in areas of high blood flow, whereas in low flow regions IEs remained




FIGURE 1 | Schematic summarizing different malarial parasites and current knowledge of infected erythrocytes (IEs) and mechanisms in humans, nonhuman primates, and rodent models of malaria in pregnancy. For more details, see **Table 1**.

stationary, indicating preferential IE adhesion in these regions⁵³. The authors suggested that in maternal blood spaces with low microcirculation, IEs might establish a stable IE-trophoblast interaction that was associated with IE adhesion in the placenta, indicating that the parasite takes advantage of the heterogeneous placental blood flow pattern to accumulate in the mouse placenta⁵³.

Because *var* genes are absent in *P. berghei*, the antigen(s) that mediates placental binding in rodent models could be identified and

might be studied as an alternative vaccine target(s). Conversely, the absence of *var* genes represents a limitation for studying VAR2CSA-based vaccines in this model. This limitation has been partially overcome in a recent report⁵⁴, where a transgenic *P. berghei* parasite was engineered to express the full-length VAR2CSA extracellular region fused to a full-length *P. berghei* exported protein (EMAP1). BALB/c mice infected at mid-gestation with *P. berghei*-VAR2CSA suffered a higher incidence of stillbirth, lower fetal weight, maternal

Box 3 | Challenges in rodent models for PM vaccine development

Parasite proteins?

Parasite proteins that may play a role in rodent models of MiP are unclear. No *var* gene encoded proteins or homologs exist in rodent parasites. Rodent parasites possess the *pir* multigene family that is related to the *P. falciparum rif* and *stevor* gene families, but little evidence regarding their function in placental adherence is known.

P. berghei binding?

Transgenic *P. berghei* parasites expressing VAR2CSA bind *in vitro* at higher numbers to placental tissue compared to wild-type *P. berghei*, however these parasites yield similar placental parasite load *in vivo*. This model needs further optimization to assess VAR2CSA-based PM vaccines, as placental binding can occur with both *P. berghei*-VAR2CSA and *P. berghei* models.

Placental anatomy and microcirculation?

Placental anatomy differs substantially between humans and rodents. These differences may contribute to different microcirculation flow and vascular niches in the placenta, and may be associated with different mechanisms of placental sequestration in rodent models.

mortality and fetal loss as compared to those infected by wild-type *P. berghei*. Notably, the parasite loads in infected placentas were similar with both parasite lines, indicating that increased virulence did not depend on parasite burden⁵⁴. VAR2CSA expression increased adhesion of *P. berghei* to placental tissue in *in vitro* assays, and induced VAR2CSA antibodies in infected mice⁵⁴. The *P. berghei*-VAR2CSA model has some limitations. Despite increased adherence to placental tissue, VAR2CSA expression by *P. berghei* exacerbated MiP pathogenicity without enhancing placental parasite load, which is unlike the pattern seen in women⁵⁴. The fact that placental binding is likely to occur in both *P. berghei*-VAR2CSA and *P. berghei* models complicates the use of the *P. berghei*-VAR2CSA model to assess VAR2CSA-based vaccine candidates under development.

Of note, placentas collected from *P. berghei*-infected mice demonstrate significant monocyte infiltration, abnormal placental formation, and the presence of *P. berghei*-IEs and hemozoin^{9,55}. However, the intense peripheral parasitemia (more than 50% infected erythrocytes) during *P. berghei* infections may have also contributed to or been responsible for the high parasite density and pathology in the placenta⁹.

The different non-immune rodent MiP models may offer an opportunity to understand pathological outcomes during pregnancy. The dysregulation of both pro-inflammatory and anti-inflammatory cytokine responses (as well as complement factors) has parallels to changes observed in infected pregnant women. In mice, these result in dysregulated vasculogenesis (differentiation of precursor cells) and angiogenesis (formation of new blood vessels) in malaria-infected placentas, and in turn, poorer birth outcomes; these relationships should be further studied in pregnant women. While the different models display some evidence of IE adhesion to placenta or of placental inflammation, the degree of sequestration does not approach that seen with *P. falciparum*, suggesting that the rodent MiP models may have limited relevance to *P. falciparum* MiP in women. Transgenic parasites expressing VAR2CSA should be further investigated to understand their usefulness to assess VAR2CSA-based vaccines. One alternative might be to establish a model using a rodent strain with no known affinity for binding to the placenta, where the placental sequestration phenotype can be induced by introducing VAR2CSA expression in transgenic parasites.

Infection before pregnancy (recrudescence model)

Parasite recrudescence is an established feature of MiP due to either *P. falciparum* or *P. vivax* in women^{56,57}. Models of recrudescence in pregnant animals could be exploited to understand its basis and any distinct effects on placental function, fetal development, and acquisition of MiP-specific immunity. In one study, mice challenged with *P. berghei* carried low grade parasitemia for months, and upon pregnancy, experienced recrudescence parasitemia which was often lethal within the first few days of pregnancy⁵⁸. Anemia, poor pregnancy outcomes, and enrichment of mature stage parasites in the placenta have been observed^{36,43}. Interestingly, recrudescence was less frequent in subsequent pregnancies and pregnancy outcomes were improved, suggesting the acquisition of specific immunity^{9,36}. Further, plasma antibodies acquired from infections before pregnancy were not reactive toward *P. berghei* parasites that were recrudescence during pregnancy, suggesting that distinct variant surface antigens (VSAs) were expressed³⁶.

With *P. chabaudi*, most mice experienced a non-lethal recrudescence during pregnancy associated with anemia⁴⁰, similar to the clinical presentation of malaria in many women. The acquisition of antibodies against the parasites has not been investigated in the *P. chabaudi* MiP model. More studies are needed to better understand the basis for recrudescence, and whether these models can be useful for PM vaccine development.

Exposure before and during pregnancy (immune model)

A model that incorporates malaria exposure before pregnancy is better suited to mimic first-time pregnant mothers in endemic regions, as most of these women have experienced malaria before pregnancy. Such models can yield insights into the impact of pre-existing immunity on malaria-related poor pregnancy outcomes, the differences and similarities between MiP-specific immunity versus general malaria immunity, and the potential for pre-existing immunity to be boosted during MiP.

P. chabaudi has the advantage of several antigenically distinct parasite lines that allow serial heterologous infections⁵⁹. Sequential infection with *P. chabaudi* AS before pregnancy and then *P. chabaudi* CB during pregnancy causes death and impaired post-natal growth of pups that is associated with inflammatory cytokines. Notably, offspring delivered by re-infected dams were more resistant to




FIGURE 2 | Illustration demonstrating key differences in placental anatomy between humans and mice.

P. chabaudi infection compared to those by never-infected dams⁴⁰. Similarly, infants born in areas of stable malaria transmission display resistance to malaria infection and disease for the first months of life, and the transfer of maternal antibodies may contribute to such protection, though the evidence for this is not yet conclusive (reviewed in ref. 60).

Both heterologous re-infection with *P. berghei* NK65 during pregnancy and homologous re-infection with *P. berghei* K173 during pregnancy led to dysregulated inflammatory responses and significantly lower birth weight of pups^{44,45}. The observations seen in re-infection models suggest that, despite previously acquired immunity, mice remain susceptible to re-infection of the same species during pregnancy, likely by parasite expression of VSA to evade pre-existing immunity as observed in the recrudescence model³⁶. Therefore, immunity acquired before pregnancy may be inadequate to confer protection during pregnancy³⁶, a pattern also seen in human studies².

Overall, rodent models that allow parasite infection before and during pregnancy may better reflect the experience of women in endemic areas, who are also exposed to malaria both before and during pregnancy. These models can be used to dissect immunopathology that ensues during pregnancy despite previously acquired immunity. They can also be interrogated to discriminate the benefits of immunity acquired against malaria generally versus MiP specifically, as well as the effect of maternal antibodies to modulate protection in offspring. Finally, such studies can lead to the identification of antigen(s) relevant to these different forms of acquired immunity, which might prompt studies of these non-VAR2CSA antigens as targets of human immunity during MiP and thereby inform future vaccine development and testing.

Limitations of rodent models for pregnancy malaria vaccine development

With their ease of use, rodent models present an attractive approach to study MiP pathogenesis and immunity. However, the absence

of PfEMP1 homologs and understanding of surface proteins that mediate pathology in rodent malaria impede their use to better understand MiP pathogenesis (see **Box 3** for rodent model limitations). Rodent parasites possess the *pir* multigene family that is related to the *P. falciparum* *rif* and *stevor* gene families, but little evidence regarding their function(s) is known⁶¹. On the other hand, the recent use of transgenic *P. berghei* parasites expressing VAR2CSA, which were shown to bind more effectively to the placenta than control parasites, may provide a viable platform for vaccine studies⁵⁴. Such models can be useful to assess anti-VAR2CSA antibodies in preventing poor pregnancy outcomes in both dams and pups. However, the limited evidence of placental sequestration with both transgenic and wild-type *P. berghei* raises concerns for their relevance to human PM.

In the *P. chabaudi*-MiP model, adverse pregnancy outcomes with limited evidence of placental sequestration suggest it may be an attractive model to study *P. vivax*-MiP⁴⁰. Although CIR protein has been implicated in rosette formation (clusters in which uninfected erythrocytes aggregate around an IE)⁶², this feature is uncommon during *P. falciparum*-MiP⁶³.

Overall, the majority of rodent MiP studies have been done using blood-stage parasite inoculation, which does not represent the natural route of infection. Future studies with rodent models should further explore sporozoite inoculation to establish infection, and whether this alters MiP presentation or acquisition of immunity. Notably, there are substantial differences in placental anatomy between humans and rodents (see **Fig. 2**). For instance, in the human placenta, the chorionic plate (involved in blood flow in maternal space) has a tree branch-like pattern, in contrast to the mouse placenta that is interconnected like a maze (reviewed in ref. 64). Such differences may contribute to different micro-circulation rates and vascular niches in the placenta, and must be taken into consideration when assessing MiP features in these rodent models.

Box 4 | Challenges in NHP models for PM vaccine development

Placental sequestration in rhesus monkeys?

No evidence of *P. coatneyi* and *P. cynomolgi* placental sequestration exists in rhesus monkeys, suggesting that a vaccine designed to prevent placental sequestration could not be assessed in these models.

P. knowlesi ligand?

P. knowlesi sequesters in the placentas of olive baboons and possibly rhesus, however the molecular basis for sequestration is unknown. Unless the *P. knowlesi* ligand for placental sequestration is identified, and orthologous proteins in *P. falciparum* are shown to be involved in human placental sequestration, this model might not be useful in PM vaccine development.

VAR2CSA orthologs?

VAR2CSA, the current leading PM vaccine candidate in humans, is exclusively expressed by *P. falciparum*, and the closely related chimpanzee parasite *P. reichenowi* with no orthologs found in *Plasmodium* species used in existing NHP models.

Protective immunity?

Existing NHP models have not been studied for the acquisition of protective immunity over successive pregnancies, as observed in women living in malaria-endemic areas. These features are needed in NHP models to assess clinical PM vaccines.

Pregnancy malaria in non-human primates

Non-human primates (NHPs) and humans share strong developmental, immunological, anatomical, and biochemical similarities, as well as physiologically similar reproductive systems^{65,66}. The hemochorial type placenta is shared by many NHPs and humans, emphasizing the potential importance of these models to understand PM pathogenesis^{67,68}. NHP models of MiP have mainly focused on two monkey species: rhesus macaques (*Macaca mulatta*)^{69,70} and baboons (*Papio anubis*)^{71,72}. While rhesus monkeys and baboons are susceptible to many *Plasmodium* species, only a few (*P. coatneyi* and *P. cynomolgi* for rhesus macaques and *P. knowlesi* for baboons) have been studied as potential MiP models. For most of these studies, only non-immune pregnant monkeys were used, so that observations from these studies to date may be most relevant to MiP in non-immune women.

P. coatneyi and *P. cynomolgi* in pregnant rhesus monkeys

P. coatneyi has several biological features in common with *P. falciparum*, such as a 48-h intra-erythrocytic developmental cycle, electron-dense knob protrusions on the surface of IE, rosette formation^{73–76}, and complete deep vascular sequestration of mature-stage IEs with predilection for specific tissues^{77–80}. In non-splenectomized pregnant rhesus monkeys of various parities, high peak parasitemia was observed seven days post-inoculation of blood stage *P. coatneyi* during the first trimester of gestation, which coincided with the loss of pregnancy in 3 out of 4 infected pregnant monkeys⁷⁰. Other adverse pregnancy outcomes were observed in 6 additional pregnant monkeys infected with reduced *P. coatneyi* inoculum (along with one monkey from the first cohort) who carried their gestations to term, including LBW, intrauterine growth restriction (IUGR), congenital infection, and infant mortality⁷⁰. Placental histology studies of *P. coatneyi*-infected pregnant monkeys revealed fibrinoid deposits, infarcts, syncytiotrophoblast disruption, inflammatory cell infiltration, malaria pigment (hemozoin), and activated macrophages⁶⁹. These placental damages are similar to those seen in humans^{12,81,82}. However, placental sequestration

of parasites does not appear to be a feature of *P. coatneyi* MiP (see section below on “Placental sequestration patterns”).

P. cynomolgi infection in pregnant rhesus monkeys has also been studied as a non-sequestering parasite model for *P. vivax* infection in pregnancy. By infecting pregnant rhesus monkeys in the third trimester of pregnancy with either *P. cynomolgi cynomolgi* or *P. cynomolgi Bastianelli*, Kamboj and Dutta⁸³ showed intensified parasitemia and significant pathology, including delayed placental retention as well as fetal, infant, and maternal mortality. Saxena and colleagues subsequently studied early gestation *P. cynomolgi* infections in rhesus monkeys to relate biochemical abnormalities with placental pathology and clinical outcomes^{84–87}. In four pregnant monkeys, inoculation of *P. cynomolgi* during the first trimester of pregnancy resulted in maternal, fetal, and newborn deaths. Histochemical studies revealed changes in hydrolytic enzyme activity in the placenta, which might directly impact functional and morphological integrity of the tissue by impairing the enzyme-mediated cellular transport mechanisms^{84,88}, and thereby contribute to embryonic deaths and abortions^{84,86,87}.

The pregnancy outcomes described in both these rhesus models are similar to those reported for human MiP, and thus support the use of *P. coatneyi* and *P. cynomolgi* as valid models to study adverse outcomes seen in pregnant women.

P. knowlesi infection in pregnant monkeys

P. knowlesi naturally infects the long-tailed macaque (*Macaca fascicularis*), and can infect other primates including baboons and humans^{89,90}. Although *P. knowlesi* clusters phylogenetically with *P. vivax*⁹¹, which has a non-sequestering phenotype, *P. knowlesi* is a partially sequestering parasite known to accumulate in several organs^{91,92}. In a study from the 1930s, Das Gupta infected a pregnant rhesus monkey with *P. knowlesi* and observed that placental blood was massively infected, while fetal blood and other maternal organs were free of parasites⁹³. However, this study has not been replicated, and additional histological evidence for placental sequestration in this model is still needed.

Table 1 | Characteristics of MiP in humans, non-human primates and rodents

Characteristics of malaria in pregnancy	Humans		Non-human primates			Rodents	
	<i>P. falciparum</i>	<i>P. vivax</i>	<i>P. knowlesi</i>	<i>P. coatneyi</i>	<i>P. cynomolgi</i>	<i>P. chabaudi</i>	<i>P. berghei</i>
Sequestration within the placenta	Yes ^{15,18,19}	No ^{12,104}	Yes ^{71,72,94}	Unclear*	No ^{84,85,105}	Unclear*	Unclear*
Inflammatory infiltrate in the placenta	Yes ²	Yes ¹⁰⁴	Yes ⁹⁴	Yes ⁶⁹	Yes ⁸⁶	No ⁵⁰	Yes ⁹
Dysregulated cytokines levels	Yes ¹⁰⁶	Yes ¹⁰⁷	Yes ⁷²	Unknown	Unknown	Yes ^{37,39}	Yes ^{35,44,45}
Placental tissue damage	Yes ^{81,82}	Yes ¹⁰⁸	Yes ⁹⁴	Yes ⁶⁹	Yes ^{84–86}	Unknown	Yes ^{9,43}
Affect placenta functions	Yes ^{109,110}	Unknown	Unknown	Yes ⁶⁹	Yes ^{84–86}	Unknown	Unknown
Maternal anemia	Yes ⁷	Yes ^{13,111}	Yes ⁹⁴	Yes ^{70,78}	Unknown	Yes ⁵⁰	Yes ³⁶
Acquisition of immunity against placental-binding parasites	Yes ²⁸	Unknown	Unknown	Unknown	Unknown	Unknown	Yes ³⁶
Outcomes of fetus							
Congenital malaria	Uncommon ¹²	Uncommon ¹⁴	No ⁹⁴	Common ⁷⁰	Unknown	Unknown	Unknown
Low birthweight	Yes ^{3,5,7}	Yes ^{13,111}	Unknown	Yes ^{69,70}	Unknown	Yes ⁴⁰	Yes ³⁶

*Insufficient evidence or contradicting reports

In olive baboons (*Papio anubis*), *P. knowlesi* infection can be acute (with multiple organ dysfunction and cerebral involvement) or chronic (with enlarged spleen) with similar clinical symptoms to those of *P. falciparum* infection in humans, including but not limited to anemia, hyperbilirubinemia, cholestasis, apathy, lethargy and coma⁶⁶. *P. knowlesi* MiP in olive baboons shares several features with human MiP, including placental sequestration; maternal anemia; accumulation of immunological cells such as macrophages, neutrophils and monocytes in the placenta; and placental tissue damage^{71,72,94}. Studies have demonstrated the accumulation of late-stage *P. knowlesi*-IEs in the intervillous spaces of the baboon placenta, increased placental parasitemia compared to peripheral parasitemia, and infiltration of inflammatory cells in the placenta leading to severe placental damage^{72,94}, demonstrating that *P. knowlesi* parasites can cytoadhere in the placenta^{71,94} despite the absence of a confirmed VAR2CSA ortholog. The SICAvAr multigene family responsible for antigenic variation in *P. knowlesi*⁹⁵ has been related to the *var* gene family in *P. falciparum*^{96,97}, but their biological function in cytoadherence and sequestration is still unknown⁹⁶. However, in homology blasts, erythrocyte binding proteins (EBP-alpha, EBP-beta and EBP-gamma) showed the greatest homology to VAR2CSA⁹⁸.

Immunological and hematological changes related to MiP have also been investigated in the *P. knowlesi*-baboon model. *P. knowlesi* infection in pregnant baboons causes elevated concentrations of TNF- α and IL-12 in placental plasma, but decreased levels of IL-4, IL-6, IL-10 and IFN- γ cytokines^{72,94}. These cytokine changes differ in some ways from those in the malaria-infected human placenta, where no change in the levels of IL-4 and IL-6 and increased levels of IFN- γ have been reported⁹⁹. In one study, all pregnant baboons developed anemia during *P. knowlesi* infection as compared to uninfected pregnant baboons⁹⁴. These reports highlight many similarities in MiP pathology in humans and the *P. knowlesi*-baboon model, the most relevant being placental sequestration and adverse sequelae. These observations support the use of the olive baboon-*P. knowlesi*

model for further MiP-related immunology studies and investigation of molecular mechanisms involved in the accumulation of non-*falciparum* parasites in the placenta.

Challenges in the use of NHP models for placental malaria vaccine development

The NHP models reported to date offer various opportunities to study MiP pathology and represent a major asset to help identify drug targets. However, some key limitations exist in order to mimic MiP pathology in humans and to obtain key clinical outcomes that can be monitored as endpoints for PM or MiP vaccine candidates (see **Box 4** for primate model limitations).

Placental sequestration patterns

Placental sequestration is absent in some models (*P. coatneyi* and *P. cynomolgi* MiP in rhesus monkeys), which may make them more suitable as models for *P. vivax* MiP. In the *P. coatneyi* model of MiP, the parasite densities in both placental and peripheral blood smears were similar at delivery⁶⁹. In addition, although IEs could be identified within the intervillous space of placental tissue sections, there was no increased accumulation of IEs within the intervillous space nor IEs adhering to the syncytiotrophoblast surface⁶⁹. The failure of *P. coatneyi* to sequester in the placenta might be related to the absence of VAR2CSA or *var* gene orthologs in *P. coatneyi*¹⁰⁰.

P. knowlesi sequesters in the placentas of olive baboons and possibly rhesus, but the molecular basis for sequestration is not yet known. In a previous report, *P. knowlesi* IEs from human subjects have been shown to bind in a specific but variable manner to the inducible endothelial receptors ICAM-1 and VCAM¹⁰¹, suggesting that VSA (distinct from PfEMP1) may be mediating cytoadherence. These observations highlight the dearth of knowledge regarding the underlying mechanisms for placental tropism of parasites in these NHP models. This also raises the question about *P. falciparum* placental sequestration and the central role of VAR2CSA as the only known ligand for parasite binding to placental tissues. Of note, no

study has conclusively established that VAR2CSA is required for placental sequestration. Overall, the biology of host-parasite interactions in the context of pregnancy merits further investigation in monkeys, including the relative contribution of sequestration in the placenta versus other organs to adverse pregnancy outcomes.

MiP-related parity effect and protection

The effect of parity on human susceptibility to MiP is well-known: in areas of stable transmission, primigravidae have the highest susceptibility to *P. falciparum* parasitemia as well as adverse pregnancy outcomes, and susceptibility decreases over successive pregnancies^{1,2,5-7,102}. This pattern has been explained by the acquisition of specific antibodies against the VSA of placental IE^{28,30}. Therefore, induction of this functional immunity that protects against MiP is the ultimate goal of PM vaccine development.

Little is known about the parity effect in existing NHP models. Parity of naïve pregnant rhesus monkeys does not influence whether the animal will develop a high or low parasitemia in *P. coatneyi* MiP^{69,70}, but this is thought to be true in naive humans as well. Further, studies of MiP in NHP models^{71,83,86,94} were not designed to address this key element of immunity to MiP. Future studies should explore the impact of malaria episodes over successive pregnancies, as well as before pregnancy, on PM in the different NHP models. This can ascertain which models best mimic MiP in endemic regions, and potentially help to understand the dynamic acquisition of protective immunity against PM.

Conclusion

One hundred twenty-five million pregnant women are at risk of *Plasmodium* infection each year¹⁰³, which causes poor outcomes including death for both mother and offspring. The underlying mechanisms of disease and death remain uncertain. Furthermore, the need for an effective vaccine has been made more urgent by the spread of drug-resistant parasites and insecticide-resistant mosquitoes. Relevant animal models could improve our understanding of MiP and accelerate development of preventive strategies. However, skepticism will remain as most of the existing models share some but not all features of MiP in humans (Table 1). A pressing need is to establish a model that is suitable to assess VAR2CSA-based vaccine candidates currently under development³¹. Importantly only the *P. falciparum* genome encodes VAR2CSA, and therefore transgenic model parasites engineered to express VAR2CSA may be useful to overcome these shortcomings in the existing models⁵⁴. Alternatively, a model that can be infected by *P. falciparum*, which is limited at present to a few New World monkeys, might be useful for studying PM pathogenesis and evaluating vaccine activity.

ACKNOWLEDGMENTS

We are thankful to J. Patrick Gorres for extensive proofreading and editing of the manuscript. The authors are supported by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases of the National Institutes of Health.

COMPETING FINANCIAL INTERESTS

The authors declare no competing financial interests.

Received 6 March 2017; accepted 25 August 2017
Published online at <http://www.nature.com/labán>

1. Brabin, B.J. An analysis of malaria in pregnancy in Africa. *Bull. World Health Organ.* **61**, 1005–1016 (1983).
2. Rogerson, S.J., Hviid, L., Duffy, P.E., Leke, R.F. & Taylor, D.W. Malaria in pregnancy: pathogenesis and immunity. *Lancet Infect. Dis.* **7**, 105–117 (2007).
3. Desai, M. *et al.* Epidemiology and burden of malaria in pregnancy. *Lancet Infect. Dis.* **7**, 93–104 (2007).
4. Nosten, F., ter Kuile, F., Maelankirri, L., Decludt, B. & White, N.J. Malaria during pregnancy in an area of unstable endemicity. *Trans. R. Soc. Trop. Med. Hyg.* **85**, 424–429 (1991).
5. Menendez, C. *et al.* The impact of placental malaria on gestational age and birth weight. *J. Infect. Dis.* **181**, 1740–1745 (2000).
6. Rogerson, S.J., Mwapasa, V. & Meshnick, S.R. Malaria in pregnancy: linking immunity and pathogenesis to prevention. *Am. J. Trop. Med. Hyg.* **77**, 14–22 (2007).
7. Steketee, R.W., Nahlen, B.L., Parise, M.E. & Menendez, C. The burden of malaria in pregnancy in malaria-endemic areas. *Am. J. Trop. Med. Hyg.* **64**, 28–35 (2001).
8. Wickramasuriya, G. *Malaria and Ankylostomiasis in the pregnant woman*, London: Oxford University Press, 1936.
9. Neres, R., Marinho, C.R., Goncalves, L.A., Catarino, M.B. & Penha-Goncalves, C. Pregnancy outcome and placenta pathology in *Plasmodium berghei* ANKA infected mice reproduce the pathogenesis of severe malaria in pregnant women. *PLoS One* 2008;3:e1608.
10. Andrews, K.T. & Lanzer, M. Maternal malaria: *Plasmodium falciparum* sequestration in the placenta. *Parasitol. Res.* **88**, 715–723 (2002).
11. Bray, R.S. & Sinden, R.E. The sequestration of *Plasmodium falciparum* infected erythrocytes in the placenta. *Trans. R. Soc. Trop. Med. Hyg.* **73**, 716–719 (1979).
12. McGready, R. *et al.* The effects of *Plasmodium falciparum* and *P. vivax* infections on placental histopathology in an area of low malaria transmission. *Am. J. Trop. Med. Hyg.* **70**, 398–407 (2004).
13. Nosten, F. *et al.* Effects of *Plasmodium vivax* malaria in pregnancy. *Lancet* **354**, 546–549 (1999).
14. Rodriguez-Morales, A.J. *et al.* Pregnancy outcomes associated with *Plasmodium vivax* malaria in northeastern Venezuela. *Am. J. Trop. Med. Hyg.* **74**, 755–757 (2006).
15. Beeson, J.G., Amin, N., Kanjala, M. & Rogerson, S.J. Selective accumulation of mature asexual stages of *Plasmodium falciparum*-infected erythrocytes in the placenta. *Infect. Immun.* **70**, 5412–5415 (2002).
16. Doritchamou, J. *et al.* First-trimester *Plasmodium falciparum* infections display a typical “placental” phenotype. *J. Infect. Dis.* **206**, 1911–1919 (2012).
17. Doritchamou, J. *et al.* Dynamics in the cytoadherence phenotypes of *Plasmodium falciparum* infected erythrocytes isolated during pregnancy. *PLoS ONE* **9**, e98577 (2014).
18. Fried, M., Domingo, G.J., Gowda, C.D., Mutabingwa, T.K. & Duffy, P.E. *Plasmodium falciparum*: chondroitin sulfate A is the major receptor for adhesion of parasitized erythrocytes in the placenta. *Exp. Parasitol.* **113**, 36–42 (2006).
19. Fried, M. & Duffy, P.E. Adherence of *Plasmodium falciparum* to chondroitin sulfate A in the human placenta. *Science* **272**, 1502–1504 (1996).
20. Scherf, A. *et al.* Antigenic variation in malaria: in situ switching, relaxed and mutually exclusive transcription of var genes during intra-erythrocytic development in *Plasmodium falciparum*. *EMBO J.* **17**, 5418–5426 (1998).
21. Tuikue Ndam, N.G. *et al.* Variable adhesion abilities and overlapping antigenic properties in placental *Plasmodium falciparum* isolates. *J. Infect. Dis.* **190**, 2001–2009 (2004).
22. Salanti, A. *et al.* Selective upregulation of a single distinctly structured var gene in chondroitin sulphate A-adhering *Plasmodium falciparum* involved in pregnancy-associated malaria. *Mol. Microbiol.* **49**, 179–191 (2003).
23. Tuikue Ndam, N.G. *et al.* High level of var2csa transcription by *Plasmodium falciparum* isolated from the placenta. *J. Infect. Dis.* **192**, 331–335 (2005).
24. Viebig, N.K. *et al.* Disruption of var2csa gene impairs placental malaria associated adhesion phenotype. *PLoS ONE* **2**, e910 (2007).
25. Baruch, D.I. *et al.* Cloning the *P. falciparum* gene encoding PFEMP1, a malarial variant antigen and adherence receptor on the surface of parasitized human erythrocytes. *Cell* **82**, 77–87 (1995).

26. Su, X.Z. *et al.* The large diverse gene family var encodes proteins involved in cytoadherence and antigenic variation of *Plasmodium falciparum*-infected erythrocytes. *Cell* **82**, 89–100 (1995).
27. Duffy, P.E. & Fried, M. Antibodies that inhibit *Plasmodium falciparum* adhesion to chondroitin sulfate A are associated with increased birth weight and the gestational age of newborns. *Infect. Immun.* **71**, 6620–6623 (2003).
28. Fried, M., Nosten, F., Brockman, A., Brabin, B.J. & Duffy, P.E. Maternal antibodies block malaria. *Nature* **395**, 851–852 (1998).
29. Ndam, N.T. *et al.* Protective Antibodies against Placental Malaria and Poor Outcomes during Pregnancy, Benin. *Emerg. Infect. Dis.* **21**, 813–823 (2015).
30. Teo, A., Feng, G., Brown, G.V., Beeson, J.G. & Rogerson, S.J. Functional Antibodies and Protection against Blood-stage Malaria. *Trends Parasitol.* **32**, 887–898 (2016).
31. Chene, A. *et al.* Clinical development of placental malaria vaccines and immunoassays harmonization: a workshop report. *Malar. J.* **15**, 476 (2016).
32. Nosten, F. *et al.* Mefloquine antimalarial prophylaxis in pregnancy: dose finding and pharmacokinetic study. *Br. J. Clin. Pharmacol.* **30**, 79–85 (1990).
33. Tegoshi, T., Desowitz, R.S., Pirl, K.G., Maeno, Y. & Aikawa, M. Placental pathology in *Plasmodium berghei*-infected rats. *Am. J. Trop. Med. Hyg.* **47**, 643–651 (1992).
34. Brugat, T. *et al.* Sequestration and histopathology in *Plasmodium chabaudi* malaria are influenced by the immune response in an organ-specific manner. *Cell. Microbiol.* **16**, 687–700 (2014).
35. Fitri, L.E. *et al.* Low Fetal Weight is Directly Caused by Sequestration of Parasites and Indirectly by IL-17 and IL-10 Imbalance in the Placenta of Pregnant Mice with Malaria. *Korean J. Parasitol.* **53**, 189–196 (2015).
36. Megnekou, R., Hviid, L. & Staaloe, T. Variant-specific immunity to *Plasmodium berghei* in pregnant mice. *Infect. Immun.* **77**, 1827–1834 (2009).
37. Poovassery, J. & Moore, J.M. Association of malaria-induced murine pregnancy failure with robust peripheral and placental cytokine responses. *Infect. Immun.* **77**, 4998–5006 (2009).
38. Rahmah, Z., Sasmito, S.D., Siswanto, B., Sardjono, T.W. & Fitri, L.E. Parasitemia induces high plasma levels of Interleukin-17 (IL-17) and low levels of Interleukin-10 (IL-10) and Transforming Growth Factor- α (TGF- α) in pregnant mice infected with malaria. *Malays. J. Med. Sci.* **22**, 25–32 (2015).
39. Sarr, D., Smith, G.M., Poovassery, J.S., Nagy, T. & Moore, J.M. *Plasmodium chabaudi* AS induces pregnancy loss in association with systemic pro-inflammatory immune responses in A/J and C57BL/6 mice. *Parasite Immunol.* **34**, 224–235 (2012).
40. Sharma, A., Conteh, S., Langhorne, J. & Duffy, P.E. Heterologous infection of pregnant mice induces low birth weight and modifies offspring susceptibility to malaria. *PLoS ONE* **11**, e0160120 (2016).
41. Su, Z. & Stevenson, M.M. Central role of endogenous gamma interferon in protective immunity against blood-stage *Plasmodium chabaudi* AS infection. *Infect. Immun.* **68**, 4399–4406 (2000).
42. Su, Z. & Stevenson, M.M. IL-12 is required for antibody-mediated protective immunity against blood-stage *Plasmodium chabaudi* AS malaria infection in mice. *J. Immunol.* **168**, 1348–1355 (2002).
43. Marinho, C.R. *et al.* Recrudescence *Plasmodium berghei* from pregnant mice displays enhanced binding to the placenta and induces protection in multigravida. *PLoS ONE* **4**, e5630 (2009).
44. Megnekou, R., Staaloe, T. & Hviid, L. Cytokine response to pregnancy-associated recrudescence of *Plasmodium berghei* infection in mice with pre-existing immunity to malaria. *Malar. J.* **12**, 387 (2013).
45. Mineo, S., Niikura, M., Inoue, S., Kuroda, M. & Kobayashi, F. Development of severe pathology in immunized pregnant mice challenged with lethal malaria parasites. *Infect. Immun.* **81**, 3865–3871 (2013).
46. Conroy, A.L. *et al.* Complement activation and the resulting placental vascular insufficiency drives fetal growth restriction associated with placental malaria. *Cell Host Microbe* **13**, 215–226 (2013).
47. Umbers, A.J., Aitken, E.H. & Rogerson, S.J. Malaria in pregnancy: small babies, big problem. *Trends Parasitol.* **27**, 168–175 (2011).
48. Silver, K.L., Zhong, K., Leke, R.G., Taylor, D.W. & Kain, K.C. Dysregulation of angiotensin is associated with placental malaria and low birth weight. *PLoS ONE* **5**, e9481 (2010).
49. Dorman, E.K. *et al.* Impaired uteroplacental blood flow in pregnancies complicated by *falciparum* malaria. *Ultrasound Obstet. Gynecol.* **19**, 165–170 (2002).
50. Poovassery, J. & Moore, J.M. Murine malaria infection induces fetal loss associated with accumulation of *Plasmodium chabaudi* AS-infected erythrocytes in the placenta. *Infect. Immun.* **74**, 2839–2848 (2006).
51. Marin-Menendez, A. *et al.* Rosetting in *Plasmodium vivax*: a cytoadhesion phenotype associated with anaemia. *PLoS Negl. Trop. Dis.* **7**, e2155 (2013).
52. Muthusamy, A. *et al.* Chondroitin sulfate proteoglycan but not hyaluronic acid is the receptor for the adherence of *Plasmodium falciparum*-infected erythrocytes in human placenta, and infected red blood cell adherence up-regulates the receptor expression. *Am. J. Pathol.* **170**, 1989–2000 (2007).
53. de Moraes, L.V., Tadokoro, C.E., Gomez-Conde, I., Olivieri, D.N. & Penha-Goncalves, C. Intravital placenta imaging reveals microcirculatory dynamics impact on sequestration and phagocytosis of *Plasmodium*-infected erythrocytes. *PLoS Pathog.* **9**, e1003154 (2013).
54. de Moraes, L.V. *et al.* Murine Model for Preclinical Studies of Var2CSA-Mediated Pathology Associated with Malaria in Pregnancy. *Infect. Immun.* **84**, 1761–1774 (2016).
55. Hviid, L., Marinho, C.R., Staaloe, T. & Penha-Goncalves, C. Of mice and women: rodent models of placental malaria. *Trends Parasitol.* **26**, 412–419 (2010).
56. Al Hammadi, A., Mitchell, M., Abraham, G.M. & Wang, J.P. Recrudescence of *Plasmodium falciparum* in a primigravida after nearly 3 years of latency. *Am. J. Trop. Med. Hyg.* **96**, 642–644 (2017).
57. Rijken, M.J. *et al.* Chloroquine resistant vivax malaria in a pregnant woman on the western border of Thailand. *Malar. J.* **10**, 113 (2011).
58. van Zon, A.A. & Eling, W.M. Depressed malarial immunity in pregnant mice. *Infect. Immun.* **28**, 630–632 (1980).
59. McLean, S.A., Pearson, C.D. & Phillips, R.S. Antigenic variation in *Plasmodium chabaudi*: analysis of parent and variant populations by cloning. *Parasite Immunol.* **8**, 415–424 (1986).
60. Dobbs, K.R. & Dent, A.E. *Plasmodium* malaria and antimalarial antibodies in the first year of life. *Parasitology* **143**, 129–138 (2016).
61. Janssen, C.S., Phillips, R.S., Turner, C.M. & Barrett, M.P. *Plasmodium* interspersed repeats: the major multigene superfamily of malaria parasites. *Nucleic Acids Res.* **32**, 5712–5720 (2004).
62. Yam, X.Y. *et al.* Characterization of the *Plasmodium* interspersed repeats (PIR) proteins of *Plasmodium chabaudi* indicates functional diversity. *Sci. Rep.* **6**, 23449 (2016).
63. Rogerson, S.J., Beeson, J.G., Mhango, C.G., Dzinjalalala, F.K. & Molyneux, M.E. *Plasmodium falciparum* rosette formation is uncommon in isolates from pregnant women. *Infect. Immun.* **68**, 391–393 (2000).
64. Georgiades, P., Ferguson-Smith, A.C. & Burton, G.J. Comparative developmental anatomy of the murine and human definitive placentae. *Placenta* **23**, 3–19 (2002).
65. Esch, E. *et al.* Summary comparison of female reproductive system in human and the cynomolgus monkey (*Macaca fascicularis*). *Toxicol. Pathol.* **36**, 171S–172S (2008).
66. Ozwara, H. *et al.* Experimental infection of the olive baboon (*Papio anubis*) with *Plasmodium knowlesi*: severe disease accompanied by cerebral involvement. *Am. J. Trop. Med. Hyg.* **69**, 188–194 (2003).
67. Saxena, N., Mohan, A., Upadhyay, S.N. & Maitra, S.C. Rhesus monkey placenta: a light and electron microscopic study. *Lab. Anim. India.* **1**, 11–23 (1992).
68. Seeley, R., Stephens, T. & Tate, P. Development, growth, aging, and genetics: anatomy and physiology, New York, McGraw Hill, 2000.
69. Davison, B.B. *et al.* Placental changes associated with fetal outcome in the *Plasmodium coatneyi*/rhesus monkey model of malaria in pregnancy. *Am. J. Trop. Med. Hyg.* **63**, 158–173 (2000).
70. Davison, B.B. *et al.* *Plasmodium coatneyi* in the rhesus monkey (*Macaca mulatta*) as a model of malaria in pregnancy. *Am. J. Trop. Med. Hyg.* **59**, 189–201 (1998).
71. Barasa, M., Gicheru, M., Kagasi, A. & Ozwara, S. Characterisation of placental malaria in olive baboons (*Papio anubis*) infected with *Plasmodium knowlesi* H strain. *Int J Integ Biol* **9**, 54–58 (2010).
72. Barasa, M. *et al.* Cytokine expression in malaria-infected non-human primate placentas. *Open Vet J* **2**, 58–64 (2012).

73. Aikawa, M., Rabbege, J.R., Udeinya, I. & Miller, L.H. Electron microscopy of knobs in Plasmodium falciparum-infected erythrocytes. *J. Parasitol.* **69**, 435–437 (1983).
74. Kawai, S., Aikawa, M. & Suzuki, M. A nonhuman primate model for severe human malaria: *Plasmodium coatneyi*-infected Japanese macaque (*Macaca fasciata*). *Tokai J. Exp. Clin. Med.* **23**, 101–102 (1998).
75. Kilejian, A., Abati, A. & Trager, W. Plasmodium falciparum and Plasmodium coatneyi: immunogenicity of “knob-like protrusions” on infected erythrocyte membranes. *Exp. Parasitol.* **42**, 157–164 (1977).
76. Tegoshi, T. *et al.* Ultrastructure of rosette formation by Plasmodium coatneyi-infected erythrocytes of rhesus. *Parasitol. Res.* **79**, 611–613 (1993).
77. Desowitz, R.S., Miller, L.H., Buchanan, R.D. & Permpnich, B. The sites of deep vascular schizogony in Plasmodium coatneyi malaria. *Trans. R. Soc. Trop. Med. Hyg.* **63**, 198–202 (1969).
78. Desowitz, R.S., Miller, L.H., Buchanan, R.D., Yuthasastrkosol, V. & Permpnich, B. Comparative studies on the pathology and host physiology of malarias. I. Plasmodium coatneyi. *Ann. Trop. Med. Parasitol.* **61**, 365–374 (1967).
79. Sein, K.K. *et al.* Sequestration pattern of parasitized erythrocytes in cerebrum, mid-brain, and cerebellum of Plasmodium coatneyi-infected rhesus monkeys (*Macaca mulatta*). *Am. J. Trop. Med. Hyg.* **49**, 513–519 (1993).
80. Smith, C.D., Brown, A.E., Nakazawa, S., Fujioka, H. & Aikawa, M. Multi-organ erythrocyte sequestration and ligand expression in rhesus monkeys infected with Plasmodium coatneyi malaria. *Am. J. Trop. Med. Hyg.* **55**, 379–383 (1996).
81. Walter, P.R., Garin, Y. & Blot, P. Placental pathologic changes in malaria. A histologic and ultrastructural study. *Am. J. Pathol.* **109**, 330–342 (1982).
82. Yamada, M. *et al.* Plasmodium falciparum associated placental pathology: a light and electron microscopic and immunohistologic study. *Am. J. Trop. Med. Hyg.* **41**, 161–168 (1989).
83. Kamboj, K. & Dutta, G.P. Severity of blood-induced *Plasmodium cynomolgi* B and *Plasmodium cynomolgi cynomolgi* infection in pregnant rhesus monkeys. *Indian J. Malariol.* **20**, 1–5 (1983).
84. Saxena, N. & Murthy, P.S. Hydrolytic enzyme activity in rhesus monkey placenta during early gestational malaria: histochemical studies. *J. Vector Borne Dis.* **42**, 135–140 (2005).
85. Saxena, N. & Murthy, P.S. Oxidoreductases in early gestational monkey placenta during maternal malarial infection: histochemical localisation. *J. Vector Borne Dis.* **44**, 116–121 (2007).
86. Saxena, N., Pandey, V.C., Saxena, P.N. & Upadhyay, S. Hydrolytic enzymes of rhesus placenta during Plasmodium cynomolgi infection: ultrastructural and biochemical studies. *Indian J. Exp. Biol.* **31**, 54–56 (1993).
87. Saxena, N., Upadhyay, S.N., Dutta, G.P., Kazim, M. & Maitra, S.C. Scanning electron microscopic studies on rhesus monkey placenta during early gestational malarial infection. *Indian J. Exp. Biol.* **26**, 712–714 (1988).
88. Wislocki, G. & Padykula, H. *Sex and internal secretions, v II*, Baltimore: William and Wilkins (1961).
89. Coatney, G.R. The simian malarias: zoonoses, anthroponoses, or both? *Am. J. Trop. Med. Hyg.* **20**, 795–803 (1971).
90. Garnham, P. *Malaria parasites and other haemosporidia*, Oxford: Blackwell Scientific Publications, 1966.
91. Escalante, A.A., Barrio, E. & Ayala, F.J. Evolutionary origin of human and primate malarias: evidence from the circumsporozoite protein gene. *Mol. Biol. Evol.* **12**, 616–626 (1995).
92. Miller, L.H., Fremont, H.N. & Luse, S.A. Deep vascular schizogony of Plasmodium knowlesi in Macaca mulatta. Distribution in organs and ultrastructure of parasitized red cells. *Am. J. Trop. Med. Hyg.* **20**, 816–824 (1971).
93. Das Gupta, B. Malarial infection in the placenta and transmission to the foetus. *Ind. Med. Gaz.* **74**, 397–399 (1939).
94. Onditi, F.I. *et al.* Parasite accumulation in placenta of non-immune baboons during Plasmodium knowlesi infection. *Malar. J.* **14**, 118 (2015).
95. al-Khedery, B., Barnwell, J.W. & Galinski, M.R. Antigenic variation in malaria: a 3' genomic alteration associated with the expression of a P. knowlesi variant antigen. *Mol. Cell* **3**, 131–141 (1999).
96. Galinski, M.R. *et al.* Plasmodium knowlesi: a superb in vivo nonhuman primate model of antigenic variation in malaria. *Parasitology* **17**, 1–16 (2017).
97. Korir, C.C. & Galinski, M.R. Proteomic studies of Plasmodium knowlesi SICA variant antigens demonstrate their relationship with P. falciparum EMP1. *Infect. Genet. Evol.* **6**, 75–79 (2006).
98. Nyamagiri, J.O., Onditi, F.I., Ochola, L., Waihenya, R. & Ozwara, H.S. Plasmodium knowlesi Ligand-receptor Process in Baboon (*Papio anubis*) Placenta. *Journal of Biol. Agric. Healthc.* **4**, 2225–093X (2014).
99. Fried, M., Muga, R.O., Misore, A.O. & Duffy, P.E. Malaria elicits type 1 cytokines in the human placenta: IFN-gamma and TNF-alpha associated with pregnancy outcomes. *J. Immunol.* **160**, 2523–2530 (1998).
100. Chien, J.T. *et al.* High-Quality Genome Assembly and Annotation for Plasmodium coatneyi, Generated Using Single-Molecule Real-Time PacBio Technology. *Genome Announc.* **4** (2016).
101. Fatih, F.A. *et al.* Cytoadherence and virulence - the case of Plasmodium knowlesi malaria. *Malar. J.* **11**, 33 (2012).
102. Brabin, B.J. *et al.* The sick placenta-the role of malaria. *Placenta* **25**, 359–378 (2004).
103. Dellicour, S., Tatem, A.J., Guerra, C.A., Snow, R.W. & ter Kuile, F.O. Quantifying the number of pregnancies at risk of malaria in 2007: a demographic study. *PLoS Med.* **7**, e1000221 (2010).
104. Ahmed, R. *et al.* Placental infections with histologically confirmed Plasmodium falciparum are associated with adverse birth outcomes in India: a cross-sectional study. *Malar. J.* **13**, 232 (2014).
105. Saxena, N. & Saxena, P. Placental pathology in rhesus monkey during malarial infection: histological studies. *Indian J. Anim. Sci.* **63**, 1227–1232 (1993).
106. Chene, A. *et al.* Placental cytokine and chemokine profiles reflect pregnancy outcomes in women exposed to Plasmodium falciparum infection. *Infect. Immun.* **82**, 3783–3789 (2014).
107. Agudelo, O.M. *et al.* Submicroscopic infection of placenta by Plasmodium produces Th1/Th2 cytokine imbalance, inflammation and hypoxia in women from north-west Colombia. *Malar. J.* **13**, 122 (2014).
108. Souza, R.M. *et al.* Placental histopathological changes associated with Plasmodium vivax infection during pregnancy. *PLoS Negl. Trop. Dis.* **7**, e2071 (2013).
109. Chandrasiri, U.P. *et al.* Insight into the pathogenesis of fetal growth restriction in placental malaria: decreased placental glucose transporter isoform 1 expression. *J. Infect. Dis.* **209**, 1663–1667 (2014).
110. Umbers, A.J. *et al.* Placental malaria-associated inflammation disturbs the insulin-like growth factor axis of fetal growth regulation. *J. Infect. Dis.* **203**, 561–569 (2011).
111. Brutus, L., Santalla, J., Schneider, D., Avila, J.C. & Deloron, P. Plasmodium vivax malaria during pregnancy, Bolivia. *Emerg. Infect. Dis.* **19**, 1605–1611 (2013).